Search results
Results From The WOW.Com Content Network
Primidone, sold under various brand names (including Mysoline), is a barbiturate medication that is used to treat partial and generalized seizures [7] and essential tremors. [8] It is taken by mouth. [7] Its common side effects include sleepiness, poor coordination, nausea, and loss of appetite. [7] Severe side effects may include suicide and ...
Main Menu. News. News
Sedation and hypnosis are the principal side effects (occasionally, they are also the intended effects) of phenobarbital. Central nervous system effects, such as dizziness, nystagmus and ataxia, are also common. In elderly patients, it may cause excitement and confusion, while in children, it may result in paradoxical hyperactivity.
Toceranib (INN [2]), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma. [3] It is the first medication developed specifically for the treatment of cancer in dogs. [4] [5] It is used as its phosphate salt, toceranib phosphate.
Dr. Mark explains how to safely sedate a dog with Benadryl by using the correct doses.
In most cases, appropriate treatment protocols cause few side effects, but white blood cell counts must be monitored. Allogeneic and autologous stem cell transplantations (as is commonly done in humans) have recently been shown to be a possible treatment option for dogs. [19] Most of the basic research on transplantation biology was generated ...
Pimobendan is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); [1] [7] and for use with concurrent therapy for congestive heart failure (e.g.,furosemide, etc.) as appropriate on a case-by-case basis. [1]
In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells. [9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [9]